1. Home
  2. INSM vs ELS Comparison

INSM vs ELS Comparison

Compare INSM & ELS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • INSM
  • ELS
  • Stock Information
  • Founded
  • INSM 1988
  • ELS 1992
  • Country
  • INSM United States
  • ELS United States
  • Employees
  • INSM N/A
  • ELS N/A
  • Industry
  • INSM Biotechnology: Pharmaceutical Preparations
  • ELS Real Estate Investment Trusts
  • Sector
  • INSM Health Care
  • ELS Real Estate
  • Exchange
  • INSM Nasdaq
  • ELS Nasdaq
  • Market Cap
  • INSM 12.5B
  • ELS 13.6B
  • IPO Year
  • INSM 2000
  • ELS 1993
  • Fundamental
  • Price
  • INSM $73.15
  • ELS $70.91
  • Analyst Decision
  • INSM Strong Buy
  • ELS Buy
  • Analyst Count
  • INSM 16
  • ELS 9
  • Target Price
  • INSM $84.29
  • ELS $73.33
  • AVG Volume (30 Days)
  • INSM 1.7M
  • ELS 1.3M
  • Earning Date
  • INSM 10-31-2024
  • ELS 10-21-2024
  • Dividend Yield
  • INSM N/A
  • ELS 2.69%
  • EPS Growth
  • INSM N/A
  • ELS 22.76
  • EPS
  • INSM N/A
  • ELS 1.95
  • Revenue
  • INSM $342,958,000.00
  • ELS $1,521,362,000.00
  • Revenue This Year
  • INSM $18.96
  • ELS N/A
  • Revenue Next Year
  • INSM $41.96
  • ELS $5.50
  • P/E Ratio
  • INSM N/A
  • ELS $36.43
  • Revenue Growth
  • INSM 22.13
  • ELS 3.35
  • 52 Week Low
  • INSM $21.92
  • ELS $59.82
  • 52 Week High
  • INSM $80.53
  • ELS $76.60
  • Technical
  • Relative Strength Index (RSI)
  • INSM 53.81
  • ELS 52.31
  • Support Level
  • INSM $70.94
  • ELS $70.11
  • Resistance Level
  • INSM $74.32
  • ELS $73.67
  • Average True Range (ATR)
  • INSM 3.01
  • ELS 1.33
  • MACD
  • INSM 0.45
  • ELS -0.01
  • Stochastic Oscillator
  • INSM 85.11
  • ELS 56.19

About INSM Insmed Incorporated

Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

About ELS Equity Lifestyle Properties Inc.

Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company currently has a portfolio of 452 properties across the U.S. with a higher concentration in the Sunbelt region with 38% of the company's properties located in Florida, 12% in Arizona, and 8% in California. Equity Lifestyle targets owning properties in attractive retirement destinations with over 70% of the company's properties either being age-restricted or having an average resident age over 55.

Share on Social Networks: